Lipoprotein Receptors Redundantly Participate in Entry of Hepatitis C Virus
暂无分享,去创建一个
Ryoichi Shima | Toru Okamoto | Ryosuke Suzuki | Yoshiharu Matsuura | Satomi Yamamoto | Kazuaki Chayama | Chikako Ono | N. Hiraga | K. Chayama | Y. Matsuura | T. Wakita | Mai Shiokawa | C. Ono | T. Okamoto | T. Fukuhara | R. Suzuki | M. Wada | Takasuke Fukuhara | Kentaro Uemura | Yukako Kawachi | Mai Shiokawa | Hiroyuki Mori | Masami Wada | Nobuhiko Hiraga | Takaji Wakita | Hiroyuki Mori | K. Uemura | Satomi Yamamoto | Yukako Kawachi | Ryoichi Shima
[1] B. Bartosch,et al. Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1–E2 Envelope Protein Complexes , 2003, The Journal of experimental medicine.
[2] R. Cortese,et al. Successful anti‐scavenger receptor class B type I (SR‐BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR‐BI‐targeting agents , 2014, Hepatology.
[3] J. Suvarna,et al. Serum lipid profile: a predictor of clinical outcome in dengue infection , 2009, Tropical medicine & international health : TM & IH.
[4] M. Lai,et al. Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III , 2012, Gut.
[5] D. Sahoo,et al. Functional Characterization of Newly-Discovered Mutations in Human SR-BI , 2012, PloS one.
[6] Charles M. Rice,et al. Role of SR-BI in HCV entry: kinetics and molecular determinants , 2009 .
[7] Dana Carroll,et al. Gene targeting using zinc finger nucleases , 2005, Nature Biotechnology.
[8] S. Emerson,et al. Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus , 2008, Proceedings of the National Academy of Sciences.
[9] J. McKeating,et al. Hepatitis C virus cell‐cell transmission in hepatoma cells in the presence of neutralizing antibodies , 2007, Hepatology.
[10] Geoffrey Dusheiko,et al. Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.
[11] Ursula Andréo,et al. The interaction of natural hepatitis C virus with human scavenger receptor SR‐BI/Cla1 is mediated by ApoB‐containing lipoproteins , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[12] P. André,et al. Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles , 2002, Journal of Virology.
[13] Seung Woo Cho,et al. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease , 2013, Nature Biotechnology.
[14] C. Rice,et al. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells , 2009, The Journal of general virology.
[15] Charles M. Rice,et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry , 2007, Nature.
[16] R. Cortese,et al. High-Avidity Monoclonal Antibodies against the Human Scavenger Class B Type I Receptor Efficiently Block Hepatitis C Virus Infection in the Presence of High-Density Lipoprotein , 2007, Journal of Virology.
[17] J. Pawlotsky,et al. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection , 2015, Hepatology.
[18] Rudolf Jaenisch,et al. One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering , 2013, Cell.
[19] M. J. Evans,et al. Hepatitis C virus host cell entry. , 2012, Current opinion in virology.
[20] D. Lavillette,et al. The Tight Junction Proteins Claudin-1, -6, and -9 Are Entry Cofactors for Hepatitis C Virus , 2008, Journal of Virology.
[21] R. Cortese,et al. Cell Entry of Hepatitis C Virus Requires a Set of Co-receptors That Include the CD81 Tetraspanin and the SR-B1 Scavenger Receptor* , 2003, Journal of Biological Chemistry.
[22] M. Houghton,et al. Binding of hepatitis C virus to CD81. , 1998, Science.
[23] William J. Rice,et al. Ultrastructural analysis of hepatitis C virus particles , 2013, Proceedings of the National Academy of Sciences.
[24] S. Wünschmann,et al. Characterization of Hepatitis C Virus (HCV) and HCV E2 Interactions with CD81 and the Low-Density Lipoprotein Receptor , 2000, Journal of Virology.
[25] Lawrence Corey,et al. Dynamics of hepatitis C virus replication in human liver. , 2003, The American journal of pathology.
[26] D. Russell,et al. Different combinations of cysteine-rich repeats mediate binding of low density lipoprotein receptor to two different proteins. , 1989, The Journal of biological chemistry.
[27] F. Chisari,et al. Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver , 2014, Hepatology.
[28] J. McKeating,et al. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. , 2011, Journal of hepatology.
[29] Lars Kaderali,et al. Apolipoprotein E Codetermines Tissue Tropism of Hepatitis C Virus and Is Crucial for Viral Cell-to-Cell Transmission by Contributing to a Postenvelopment Step of Assembly , 2013, Journal of Virology.
[30] G. Church,et al. Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. , 2011, Nature biotechnology.
[31] K. Shimotohno,et al. Hepatitis C virus utilizes VLDLR as a novel entry pathway , 2015, Proceedings of the National Academy of Sciences.
[32] Marco M. Domingues,et al. Understanding dengue virus capsid protein disordered N-Terminus and pep14-23-based inhibition. , 2015, ACS chemical biology.
[33] Jieyun Jiang,et al. Human Apolipoprotein E Is Required for Infectivity and Production of Hepatitis C Virus in Cell Culture , 2007, Journal of Virology.
[34] Christopher T. Jones,et al. A Human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo , 2012, Hepatology.
[35] T. Hu,et al. Role of hepatitis C virus substitutions and interleukin‐28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response‐guided therapy , 2013, Journal of viral hepatitis.
[36] Olivier Poch,et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy , 2011, Nature Medicine.
[37] Charles M. Rice,et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells , 2009, Nature.
[38] Ralf Bartenschlager,et al. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81 , 2007, Hepatology.
[39] Y. Maehara,et al. Expression of MicroRNA miR-122 Facilitates an Efficient Replication in Nonhepatic Cells upon Infection with Hepatitis C Virus , 2012, Journal of Virology.
[40] Ralf Bartenschlager,et al. Characterization of Hepatitis C Virus Particle Subpopulations Reveals Multiple Usage of the Scavenger Receptor BI for Entry Steps* , 2012, The Journal of Biological Chemistry.
[41] Christopher T. Jones,et al. Different Requirements for Scavenger Receptor Class B Type I in Hepatitis C Virus Cell-Free versus Cell-to-Cell Transmission , 2013, Journal of Virology.
[42] T. Dragic,et al. Different Domains of CD81 Mediate Distinct Stages of Hepatitis C Virus Pseudoparticle Entry , 2006, Journal of Virology.
[43] V. Agnello,et al. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[44] Hongwei Li,et al. Human Apolipoprotein A-I Is Associated with Dengue Virus and Enhances Virus Infection through SR-BI , 2013, PloS one.
[45] L. Kaderali,et al. Isolate‐dependent use of claudins for cell entry by hepatitis C virus , 2014, Hepatology.
[46] A. Folgori,et al. Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. , 2012, Journal of hepatology.
[47] M. J. Evans,et al. Temporal Analysis of Hepatitis C Virus Cell Entry with Occludin Directed Blocking Antibodies , 2013, PLoS pathogens.
[48] R. D. del Ángel,et al. The increase in cholesterol levels at early stages after dengue virus infection correlates with an augment in LDL particle uptake and HMG-CoA reductase activity. , 2013, Virology.
[49] Y. Shimizu,et al. Infectivity of Hepatitis C Virus Is Influenced by Association with Apolipoprotein E Isoforms , 2010, Journal of Virology.
[50] Sangeeta N. Bhatia,et al. Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system , 2010, Nature Biotechnology.
[51] M. Imamura,et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor , 2011, Nature Medicine.
[52] R. Cortese,et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus , 2002, The EMBO journal.
[53] J. V. D. van der Meer,et al. Changes in the plasma lipid profile as a potential predictor of clinical outcome in dengue hemorrhagic fever. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[54] Emily M. Lee,et al. Cell Death-Inducing DFFA-Like Effector b Is Required for Hepatitis C Virus Entry into Hepatocytes , 2014, Journal of Virology.
[55] M. Hayden,et al. Novel mutations in scavenger receptor BI associated with high HDL cholesterol in humans , 2011, Clinical genetics.
[56] H. Wedemeyer,et al. Natural history of acute and chronic hepatitis C. , 2012, Best practice & research. Clinical gastroenterology.
[57] Charles M. Rice,et al. Role of Scavenger Receptor Class B Type I in Hepatitis C Virus Entry: Kinetics and Molecular Determinants , 2009, Journal of Virology.
[58] M. Ronaghi,et al. Ontology-Based Meta-Analysis of Global Collections of High-Throughput Public Data , 2010, PloS one.
[59] Xijun Song,et al. Claudin-6 and Claudin-9 Function as Additional Coreceptors for Hepatitis C Virus , 2007, Journal of Virology.
[60] James E. DiCarlo,et al. RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.
[61] T. Asahara,et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. , 2004, The American journal of pathology.
[62] S. Emerson,et al. Apolipoprotein C1 Association with Hepatitis C Virus , 2008, Journal of Virology.
[63] Johan Neyts,et al. The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination , 2013, Hepatology.
[64] F. Chisari,et al. Cellular Determinants of Hepatitis C Virus Assembly, Maturation, Degradation, and Secretion , 2007, Journal of Virology.
[65] M. Gale,et al. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. , 2009, Virology.
[66] V. Johnson,et al. Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. , 2014, The Journal of infectious diseases.
[67] A. Burt,et al. Association between Hepatitis C Virus and Very-Low-Density Lipoprotein (VLDL)/LDL Analyzed in Iodixanol Density Gradients , 2006, Journal of Virology.
[68] K. Shimotohno,et al. Apolipoprotein E, but Not Apolipoprotein B, Is Essential for Efficient Cell-to-Cell Transmission of Hepatitis C Virus , 2015, Journal of Virology.